Aurentz Vincent 4

What Happened Vincent Aurentz, a director of Inhibikase Therapeutics, was granted a derivative award of 155,000 shares (reported as Acquisition/Grant "A") on June 26, 2026. The Form 4 records the acquisition price as $0. This is a director compensation award rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-26; Form 4 filed: 2026-06-30 (appears timely under the two-business-day rule).
• Shares/units granted: 155,000 (reported as a derivative award); reported acquisition price: $0.
• Shares owned after transaction: not specified in the provided filing details.
• Footnote: The award vests on the earlier of June 26, 2027 or the day prior to the next annual meeting of stockholders, subject to Aurentz’s continued service.
• Transaction code: "A" (award/grant); no 10b5-1 plan, tax withholding, or cashless-sale notes reported in the provided data.

Context Director equity awards are common as non-cash compensation and do not necessarily reflect a personal buy or sell decision. Because this is a derivative award with a vesting schedule, the shares are not immediately transferable and will vest only if the director remains in service through the stated vesting date. The filing shows no immediate cash value on record; any accounting or market value would depend on company stock price and option/award terms not detailed in the excerpt.